Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 14;4(1):e000607.
doi: 10.1136/rmdopen-2017-000607. eCollection 2018.

Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study

Cem Gabay  1 , Jérôme Msihid  2 , Moshe Zilberstein  3 , Caroline Paccard  2 , Yong Lin  4 , Neil M H Graham  5 , Anita Boyapati  5
Affiliations

Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study

Cem Gabay et al. RMD Open. .

Abstract

Introduction: Interleukin-6 (IL-6) orchestrates formation of an inflammatory pannus, leading to joint damage in rheumatoid arthritis (RA). Sarilumab is a human monoclonal antibody blocking the IL-6Rα. In TARGET (NCT01709578), a phase 3 study in adults with moderate-to-severe RA and inadequate response or intolerance to tumour necrosis factor inhibitors, subcutaneous sarilumab 200 mg or 150 mg every 2 weeks (q2w) plus conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) significantly reduced disease activity versus placebo plus csDMARDs.

Methods: Circulating levels of biomarkers associated with synovial inflammation (matrix metalloproteinase 3 (MMP-3), collagen type I MMP-cleaved fragment (C1M), collagen type III MMP-cleaved fragment (C3M)), myeloid (soluble intercellular adhesion molecule 1 (sICAM-1), IL-8 and calprotectin) and lymphoid activation (chemokine, CXC motif, ligand 13 (CXCL13), CXCL10, B cell-activating factor) and bone remodelling (receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin and osteocalcin) were evaluated in patients from a TARGET substudy.

Results: Sarilumab significantly decreased C1M, C3M, CXCL13, MMP-3 and total RANKL levels at week 24 versus placebo; some markers were significantly suppressed at week 2 and normalised to levels in healthy controls. Levels of sICAM-1 were predictive of disease activity score by C-reactive protein and clinical disease activity index low disease activity (LDA) response in the sarilumab 200 mg q2w group at week 12. A trend was observed in which patients with lower sICAM-1 levels at baseline had better response compared with patients with higher sICAM-1.

Conclusions: Sarilumab plus csDMARDs decreased circulating biomarkers of synovial inflammation and bone resorption; sICAM-1 was predictive of achieving LDA with sarilumab.

Trial registration number: NCT01709578; Post-results.

Keywords: dmards (biologic); rheumatoid arthritis; treatment.

PubMed Disclaimer

Conflict of interest statement

Competing interests: CG has received consulting fees from Roche, Merck, AbbVie, Pfizer, Bristol-Myers Squibb, Sanofi and AB2 Bio. JM, MZ and CP are employees of Sanofi R&D and may hold stock and/or stock options in the company. YL is an employee of Sanofi Genzyme and may hold stock and/or stock options in the company. NMHG and AB are employees of Regeneron Pharmaceuticals, Inc, and may hold stock and/or stock options in the company.

Figures

Figure 1
Figure 1
Median per cent change (error bars represent the quartile ranges Q1–Q3) from baseline in biomarkers of (A) acute-phase response (CRP), (B and C) synovial inflammation (C3M and MMP-3), (D) tissue destruction (C1M), (E) bone resorption (tRANKL) and (F) lymphoid RA synovial phenotype (CXCL13). ANOVA-type method was implemented. *Adjusted P<0.05 versus placebo; **adjusted P<0.01 versus placebo; †adjusted P<0.01 versus sarilumab 150 mg q2w (Benjamini-Hochberg procedure); ‡nominal P<0.0001 versus placebo (CRP only); §nominal P<0.0001 versus sarilumab 150 mg q2w (CRP only). ANOVA, analysis of variance; C1M, collagen type I MMP-cleaved fragment; C3M, collagen type III MMP-cleaved fragment; CRP, C-reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; CXCL13, chemokine, CXC motif, ligand 13; MMP, matrix metalloproteinase; q2w, every 2 weeks; RA, rheumatoid arthritis; tRANKL, total receptor activator of nuclear factor-κB ligand.
Figure 2
Figure 2
Percentage of patients in each treatment group whose biomarker values returned to normal reference ranges at week 24. C1M, collagen type I MMP-cleaved fragment; C3M, collagen type III MMP-cleaved fragment; CRP, C reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; CXCL13, chemokine, CXC motif, ligand 13; MMP, matrix metalloproteinase; q2w, every 2 weeks; RANKL, receptor activator of nuclear factor-κB ligand. *P<0.05 versus placebo; †P<0.01 versus placebo; ‡P<0.0001 versus placebo (χ2 test, unadjusted P values).
Figure 3
Figure 3
Odds ratios for achieving ACR50 response, ACR70 response, DAS28-CRP LDA, DAS28-CRP remission and CDAI LDA at weeks 12 and 24. High, >median value in overall treatment groups; low, ≤median value in overall treatment groups. Median concentrations of biomarkers are 83.42 ng/mL (C1M), 49.70 ng/mL (MMP-3), 301.84 pg/mL (CXCL10), 19.90 pg/mL (IL-8), 132.33 pg/mL (CXCL13), 0.14 pmol/L (free RANKL), 1071.90 pg/mL (BAFF), 5.47 pmol/L (OPG) and 291.0 ng/mL (sICAM-1). ACR50/70, American College of Rheumatology 50%/70% improvement; BAFF, B cell-activating factor; CDAI, clinical disease activity index; C1M, collagen type I MMP-cleaved fragment; CXCL, chemokine, CXC motif, ligand; CDAI, clinical disease activity index; CRP, C-reactive protein; DAS28-CRP, 28-joint disease activity by CRP; LDA, low disease activity; MMP-3, matrix metalloproteinase 3; np, number of responders with placebo treatment; nt, number of responders with sarilumab treatment; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-κB ligand; sICAM-1, soluble intercellular adhesion molecule 1.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis 2010;2:247–56. 10.1177/1759720X10378372 - DOI - PMC - PubMed
    1. Sebba A. Tocilizumab: the first interleukin-6-receptor inhibitor. Am J Health Syst Pharm 2008;65:1413–8. 10.2146/ajhp070449 - DOI - PubMed
    1. Desgeorges A, Gabay C, Silacci P, et al. . Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol 1997;24:1510–6. - PubMed
    1. Sack U, Kinne RW, Marx T, et al. . Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int 1993;13:45–51. 10.1007/BF00307733 - DOI - PubMed
    1. Usón J, Balsa A, Pascual-Salcedo D, et al. . Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J Rheumatol 1997;24:2069–75. - PubMed

Associated data